Volume 12 Supplement 1

17th International Confernce on Human Retroviruses: HTLV and Related Viruses

Open Access

Circulating exosomes as an enriched source for adult T-cell leukemia biomarkers

  • Sucharita Dutta1,
  • Elizabeth Broughman1,
  • Lifang Yang1, 2,
  • Scott Peterson3,
  • Amol Prakash4 and
  • O John Semmes1, 2
Retrovirology201512(Suppl 1):P33

https://doi.org/10.1186/1742-4690-12-S1-P33

Published: 28 August 2015

ATL arises from HTLV-1-mediated transformation of infected T-cells following on average 30+ years post initial infection. Current diagnosis relies upon evaluation of numerous clinical factors and is generally effective for overt Acute and Lymphomatous variants of ATL for which survival is less than 1 year post-diagnosis. As the vast majority of infected individuals >95% will remain disease free and as a significant proportion of those that do develop ATL are “curable/treatable” there is a clear need for early definitive diagnosis of HTLV-1-infected individuals. We hypothesized that immune evasion by HTLV-1 and crosstalk between complement, fibrinolysis and coagulation (critical to hematopoietic stem cell renewal) provide pathway-specific biomarker events that are concentrated in circulating exosomes. We subjected exosomes isolated from serum of HTLV-1-infected patients to quantitative ultra-high resolution mass spectrometry that identified 784 proteins of which 208 displayed significant expression differences. We further analyzed our data with customized algorithms designed to facilitate a targeted analysis of the potential biomarker candidates inclusive of complex post-translational modifications. This approach allowed for high confidence quantitation of a panel of proteins that effectively discriminate between AS/HAM/ATL. We observed stratification of the disease states across the complement superfamily, over expression of the coagulation proteolytic cascade in HAM/TSP and ATL, and over expression of alpha-1-antitrypsin in ATL. When compared to a parallel analysis of total serum, exosomes reproducibility reflected expected tumor cell phenotype. For example, plasminogen activator inhibitor was over expressed; where as fibrinogen and metalloproteinases were downregulated in ATL exosomes. This is consistent with the function of PAI-1 to inhibit fibrinogen and MMPs. Interestingly, PAI-1 is not normally over expressed in hematopoietic disorders except Acute Lymphocytic Leukemia. We also identified APOBEC3H, which has been reported to bind specifically to HTLV-1 gag, as over expressed in ATL. We also examined the exosomes for evidence of HTLV-1 proteins. We were able to identify Tax and to a lesser extent Hbz each showing a trend of no-expression in AS, detectable expression in HAM/TSP and higher expression in ATL.

Authors’ Affiliations

(1)
The Leroy T. Canoles Jr. Cancer Research Center, Eastern Virginia Medical School
(2)
Department of Microbiology and Molecular Cell Biology, Eastern Virginia Medical School
(3)
Thermo Fisher Scientific BRIMS Center
(4)
Optys Tech Corporation

Copyright

© Dutta et al. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement